Compare Stocks

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BXRX Baudax Bio	$0.02 +7.4%	$0.02	$0.01 ▼ $3.47	$1.14M	1.57	281,029 shs	310,800 shs
CTYX Curative Biotechnology	$0.03	$0.03	$0.00 ▼ $0.22	$10.44M	-33.99	3.01 million shs	21,466 shs
EMMA Emmaus Life Sciences	$0.11	$0.11	$0.05 ▼ $0.35	$7.04M	1.61	2,750 shs	N/A
GRNV GreenVision Acquisition		$10.89	$7.70 ▼ $25.30	$37K	0.07	105,738 shs	1.54 million shs

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BXRX Baudax Bio	0.00%	0.00%	0.00%	-20.44%	-99.00%
CTYX Curative Biotechnology	-4.07%	+11.92%	-5.75%	+3.31%	+58.00%
EMMA Emmaus Life Sciences	0.00%	+8.33%	+32.73%	+42.19%	-65.53%
GRNV GreenVision Acquisition	0.00%	0.00%	0.00%	-61.93%	-99.35%

AI “wealth window” is closing soon! (Ad)

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BXRX Baudax Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BXRX Baudax Bio	N/A	N/A	N/A	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BXRX Baudax Bio	$1.27M	0.90	N/A	N/A	($14.93) per share	0.00
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	$18.39M	0.38	N/A	N/A	($0.69) per share	-0.16
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BXRX Baudax Bio	-$58.79M	-$9.23	N/A	N/A	N/A	N/A	N/A	-175.11%	5/10/2024 (Estimated)
CTYX Curative Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	-$10.62M	-$0.10	N/A	∞	N/A	-16.66%	N/A	-9.73%	N/A
GRNV GreenVision Acquisition	-$510K	N/A	0.00	N/A	N/A	N/A	-54.82%	-2.65%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BXRX Baudax Bio	N/A	N/A	N/A	N/A	N/A
CTYX Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	N/A	N/A	N/A	N/A
GRNV GreenVision Acquisition	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BXRX Baudax Bio	N/A	0.07	0.07
CTYX Curative Biotechnology	N/A	N/A	N/A
EMMA Emmaus Life Sciences	N/A	0.15	0.12
GRNV GreenVision Acquisition	N/A	0.29	0.29

Ownership

Institutional Ownership

Company	Institutional Ownership
BXRX Baudax Bio	9.05%
CTYX Curative Biotechnology	N/A
EMMA Emmaus Life Sciences	7.42%
GRNV GreenVision Acquisition	N/A

Insider Ownership

Company	Insider Ownership
BXRX Baudax Bio	0.10%
CTYX Curative Biotechnology	N/A
EMMA Emmaus Life Sciences	35.00%
GRNV GreenVision Acquisition	42.90%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BXRX Baudax Bio	9	52.46 million	52.41 million	Not Optionable
CTYX Curative Biotechnology	N/A	388.50 million	N/A	Not Optionable
EMMA Emmaus Life Sciences	54	61.85 million	40.20 million	Not Optionable
GRNV GreenVision Acquisition	N/A	3.35 million	N/A	Not Optionable

GRNV, EMMA, BXRX, and CTYX Headlines

Source	Headline
	Helbiz IPO (HLBZ) Stock benzinga.com - August 20 at 6:09 PM
	SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of GreenVision Acquisition Corp. (Nasdaq fintechzoom.com - August 17 at 1:37 AM
	Scooter-Share Helbiz’s Friday 13th Debut Shows SPAC Refunds finance.yahoo.com - August 13 at 5:28 PM
	Why GreenVision's Stock Is Skyrocketing Today msn.com - August 13 at 5:28 PM
	Helbiz, Inc. and Greenvision Acquisition Corp. Announce Closing of Business Combination; Helbiz to Trade on Nasdaq Under Symbol "HLBZ" finance.yahoo.com - August 13 at 8:04 AM
	Helbiz Partners with Lightning eMotors to Deploy Electric Vehicles for Fleet Management finance.yahoo.com - July 30 at 8:47 AM
	Micro-Mobility Leader, Helbiz, Launches E-Scooters in Reggio Emilia, Italy finance.yahoo.com - July 26 at 12:47 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Baudax Bio

NASDAQ:BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

Curative Biotechnology

OTCMKTS:CTYX

Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.

Emmaus Life Sciences

OTCMKTS:EMMA

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

GreenVision Acquisition

NASDAQ:GRNV

As of April 1, 2021, operates as a subsidiary of Helbiz, Inc..

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial